In recent years, a wrench has been thrown into the patient care equation.
With 5 rheumatology biosimilars already approved by the FDA, and dozens more in the pipeline, the landscape of the rheumatology drug market is on the cusp of a major shift. Biosimilars were created to bring notoriously expensive biologic drugs to patients at lower prices. In theory, they increase access to life-changing, even life-saving, treatments. As a practicing rheumatologist in downtown Washington, DC, I observe firsthand the power of biologics to bring relief to patients suffering from crippling diseases of the joints.
In recent years, however, a wrench has been thrown into the patient care equation. Pharmacy benefit managers, better known as PBMs, were created to negotiate prices with pharmaceutical manufacturers on behalf of insurance companies and manage drug benefits. Based on my experience as a rheumatologist, I believe that PBMs, however, have evolved from their original administrative function and now wield increasing influence over which drugs are prescribed and what patients pay.
As new biosimilars enter the market, PBMs will evaluate clinical and analytical data to determine which drugs to include on their formularies, the list of medications a PBM will cover. But performance will not be their sole consideration. A spot on a PBM’s formulary is a valuable commodity. PBMs pressure drugmakers to grant them high rebates in exchange for a favorable position on their list of approved drugs. This rebate system is destructive to the biosimilars market, hinders patient care, and costs consumers billions.
Long story short, rebates don’t lower drug prices—they drive them up even higher. If a biologic manufacturer offers PBMs a high rebate, a biosimilar of that biologic trying to break into the market will have trouble succeeding. Rebates reduce competition, and consequently, reduce cost savings for patients. To make the situation even worse, PBMs absorb all or most of the rebate savings. Meanwhile, patients have little or no clue where their money is going.
The rebate system thrives on lack of transparency. Clinicians and patients have no way of knowing whether a biosimilar is on a formulary due to strong evidence of its effectiveness, or the manufacturer simply offered the PBM a higher rebate than the competition. Without transparency and fair competition, we can’t determine how effectively biosimilars reduce pharmacy-counter sticker shock and put vital treatments in people’s hands.
The medical community must come together to demand greater transparency in drug pricing, starting with PBMs. Too few people know that PBMs exist, much less understand how they contribute to skyrocketing healthcare costs. Fed up with PBMs interfering with treatment, a group of patient advocacy organizations and medical associations formed the Alliance for Transparent and Affordable Prescriptions (ATAP), a coalition that works to raise awareness about harmful PBM practices. To learn more or get involved, visit www.ATAPAdvocates.com.
The writer is a rheumatologist in private practice in Washington, DC. He is vice chair of the Alliance for Transparent and Affordable Prescriptions (ATAP).
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.